Foghorn Therapeutics Secures $50M Equity Financing at Premium, Extends Cash Runway to H1 2028

summarizeSummary

Foghorn Therapeutics announced a $50 million equity financing with leading life sciences investors, priced at a premium to its recent closing price, significantly extending its cash runway into the first half of 2028.

check_boxKey Events

• $50 Million Equity Financing Completed

  Foghorn Therapeutics entered into securities purchase agreements to raise approximately $50.0 million in gross proceeds. The offering included 2,030,314 shares of common stock and 5,421,250 pre-funded warrants, totaling 7,451,564 common stock equivalents.

• Premium Pricing and Investor Confidence

  The shares were offered at $6.71 per share, a 30% premium to the closing stock price on January 9, 2026, and above the current stock price of $5.35. The financing attracted leading life sciences investors, including BVF Partners, Deerfield Management, and Flagship Pioneering.

• Warrants Issued with High Exercise Prices

  The offering also included two series of warrants to purchase an aggregate of 7,451,564 shares, with initial exercise prices of $13.42 and $20.13 per share, signaling long-term investor confidence.

• Extended Cash Runway to Mid-2028

  The capital raise significantly strengthens the company's balance sheet, extending its cash, cash equivalents, and marketable securities of $208.9 million (inclusive of proceeds) into the first half of 2028.

auto_awesomeAnalysis

Foghorn Therapeutics successfully raised $50 million through an equity financing, a critical move for a life sciences company. The offering was priced at $6.71 per share, representing a 30% premium to the closing stock price on January 9, 2026, and above the current stock price of $5.35. This premium pricing, coupled with the participation of leading life sciences investors, signals strong confidence in the company's prospects despite the inherent dilution. The financing significantly bolsters the balance sheet, extending the company's cash runway into the first half of 2028, which is a crucial de-risking event for its ongoing pipeline development. The offering also included Series Warrants with exercise prices of $13.42 and $20.13, further indicating investor belief in future share price appreciation. While dilutive, this capital infusion provides essential funding for advancing its clinical and preclinical programs, including the Phase 1 trial of FHD-909 and several degrader programs.